Cargando…
Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics
Islet amyloidosis by IAPP contributes to pancreatic β-cell death in diabetes, but the nature of toxic IAPP species remains elusive. Using concurrent time-resolved biophysical and biological measurements, we define the toxic species produced during IAPP amyloid formation and link their properties to...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940161/ https://www.ncbi.nlm.nih.gov/pubmed/27213520 http://dx.doi.org/10.7554/eLife.12977 |
_version_ | 1782442109880500224 |
---|---|
author | Abedini, Andisheh Plesner, Annette Cao, Ping Ridgway, Zachary Zhang, Jinghua Tu, Ling-Hsien Middleton, Chris T Chao, Brian Sartori, Daniel J Meng, Fanling Wang, Hui Wong, Amy G Zanni, Martin T Verchere, C Bruce Raleigh, Daniel P Schmidt, Ann Marie |
author_facet | Abedini, Andisheh Plesner, Annette Cao, Ping Ridgway, Zachary Zhang, Jinghua Tu, Ling-Hsien Middleton, Chris T Chao, Brian Sartori, Daniel J Meng, Fanling Wang, Hui Wong, Amy G Zanni, Martin T Verchere, C Bruce Raleigh, Daniel P Schmidt, Ann Marie |
author_sort | Abedini, Andisheh |
collection | PubMed |
description | Islet amyloidosis by IAPP contributes to pancreatic β-cell death in diabetes, but the nature of toxic IAPP species remains elusive. Using concurrent time-resolved biophysical and biological measurements, we define the toxic species produced during IAPP amyloid formation and link their properties to induction of rat INS-1 β-cell and murine islet toxicity. These globally flexible, low order oligomers upregulate pro-inflammatory markers and induce reactive oxygen species. They do not bind 1-anilnonaphthalene-8-sulphonic acid and lack extensive β-sheet structure. Aromatic interactions modulate, but are not required for toxicity. Not all IAPP oligomers are toxic; toxicity depends on their partially structured conformational states. Some anti-amyloid agents paradoxically prolong cytotoxicity by prolonging the lifetime of the toxic species. The data highlight the distinguishing properties of toxic IAPP oligomers and the common features that they share with toxic species reported for other amyloidogenic polypeptides, providing information for rational drug design to treat IAPP induced β-cell death. DOI: http://dx.doi.org/10.7554/eLife.12977.001 |
format | Online Article Text |
id | pubmed-4940161 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-49401612016-07-13 Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics Abedini, Andisheh Plesner, Annette Cao, Ping Ridgway, Zachary Zhang, Jinghua Tu, Ling-Hsien Middleton, Chris T Chao, Brian Sartori, Daniel J Meng, Fanling Wang, Hui Wong, Amy G Zanni, Martin T Verchere, C Bruce Raleigh, Daniel P Schmidt, Ann Marie eLife Biochemistry Islet amyloidosis by IAPP contributes to pancreatic β-cell death in diabetes, but the nature of toxic IAPP species remains elusive. Using concurrent time-resolved biophysical and biological measurements, we define the toxic species produced during IAPP amyloid formation and link their properties to induction of rat INS-1 β-cell and murine islet toxicity. These globally flexible, low order oligomers upregulate pro-inflammatory markers and induce reactive oxygen species. They do not bind 1-anilnonaphthalene-8-sulphonic acid and lack extensive β-sheet structure. Aromatic interactions modulate, but are not required for toxicity. Not all IAPP oligomers are toxic; toxicity depends on their partially structured conformational states. Some anti-amyloid agents paradoxically prolong cytotoxicity by prolonging the lifetime of the toxic species. The data highlight the distinguishing properties of toxic IAPP oligomers and the common features that they share with toxic species reported for other amyloidogenic polypeptides, providing information for rational drug design to treat IAPP induced β-cell death. DOI: http://dx.doi.org/10.7554/eLife.12977.001 eLife Sciences Publications, Ltd 2016-05-23 /pmc/articles/PMC4940161/ /pubmed/27213520 http://dx.doi.org/10.7554/eLife.12977 Text en © 2016, Abedini et al http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Biochemistry Abedini, Andisheh Plesner, Annette Cao, Ping Ridgway, Zachary Zhang, Jinghua Tu, Ling-Hsien Middleton, Chris T Chao, Brian Sartori, Daniel J Meng, Fanling Wang, Hui Wong, Amy G Zanni, Martin T Verchere, C Bruce Raleigh, Daniel P Schmidt, Ann Marie Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics |
title | Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics |
title_full | Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics |
title_fullStr | Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics |
title_full_unstemmed | Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics |
title_short | Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics |
title_sort | time-resolved studies define the nature of toxic iapp intermediates, providing insight for anti-amyloidosis therapeutics |
topic | Biochemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940161/ https://www.ncbi.nlm.nih.gov/pubmed/27213520 http://dx.doi.org/10.7554/eLife.12977 |
work_keys_str_mv | AT abediniandisheh timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT plesnerannette timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT caoping timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT ridgwayzachary timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT zhangjinghua timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT tulinghsien timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT middletonchrist timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT chaobrian timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT sartoridanielj timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT mengfanling timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT wanghui timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT wongamyg timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT zannimartint timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT vercherecbruce timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT raleighdanielp timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT schmidtannmarie timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics |